[{"id":"4da35385-bc68-447a-9f55-d20c695bb000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04407741","created_at":"2021-01-18T21:15:24.844Z","updated_at":"2024-07-02T16:35:26.534Z","phase":"Phase 1/2","brief_title":"Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas","source_id_and_acronym":"NCT04407741","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-12"},{"id":"6fe8f0e9-8178-43af-8474-eda668b88de5","acronym":"MULAN","url":"https://clinicaltrials.gov/study/NCT04355858","created_at":"2021-01-18T21:03:24.371Z","updated_at":"2024-07-02T16:36:06.637Z","phase":"Phase 2","brief_title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","source_id_and_acronym":"NCT04355858 - MULAN","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR7390 • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 319","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-07-26"},{"id":"5642ea75-db05-4a40-a357-1d82d3c86f87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03603951","created_at":"2021-01-18T17:43:03.285Z","updated_at":"2024-07-02T16:36:11.242Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms","source_id_and_acronym":"NCT03603951","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" EZH2 mutation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zeprumetostat (SHR-2554)"],"overall_status":"Recruiting","enrollment":" Enrollment 231","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 02/14/2023","primary_completion_date":" 02/14/2023","study_txt":" Completion: 08/14/2023","study_completion_date":" 08/14/2023","last_update_posted":"2022-04-29"}]